BG97446A - Фармацевтични състави на 5-(2-хлор-1-хидроксиетил)- 4-метилтиазол - Google Patents

Фармацевтични състави на 5-(2-хлор-1-хидроксиетил)- 4-метилтиазол

Info

Publication number
BG97446A
BG97446A BG97446A BG9744693A BG97446A BG 97446 A BG97446 A BG 97446A BG 97446 A BG97446 A BG 97446A BG 9744693 A BG9744693 A BG 9744693A BG 97446 A BG97446 A BG 97446A
Authority
BG
Bulgaria
Prior art keywords
methylthiazole
hydroxyethyl
chloro
pharmaceutical compositions
solvate
Prior art date
Application number
BG97446A
Other languages
English (en)
Inventor
Bernard Boar
Alan Cross
Alfred Green
Curt-Eric Hagberg
Original Assignee
Aktiebolaget Astra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aktiebolaget Astra filed Critical Aktiebolaget Astra
Publication of BG97446A publication Critical patent/BG97446A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Фармацевтичните състави се използват за профилактика и лечение на невродегенерация или за постиганена успокоителен или антиконвулсивен ефект. Те включват 5-/2-хлор-1-хидроксиетил/-4-метилтиазол или оптични изомери, или фармацевтично приемлива сол или неин солват. 35 претенции
BG97446A 1990-08-15 1993-02-15 Фармацевтични състави на 5-(2-хлор-1-хидроксиетил)- 4-метилтиазол BG97446A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9002659A SE9002659D0 (sv) 1990-08-15 1990-08-15 New pharmaceutical formulations
PCT/SE1991/000522 WO1992003134A1 (en) 1990-08-15 1991-08-07 New pharmaceutical formulations of 5-(2-chloro-1-hydroxyethyl)-4-methylthiazole

Publications (1)

Publication Number Publication Date
BG97446A true BG97446A (bg) 1994-03-24

Family

ID=20380161

Family Applications (1)

Application Number Title Priority Date Filing Date
BG97446A BG97446A (bg) 1990-08-15 1993-02-15 Фармацевтични състави на 5-(2-хлор-1-хидроксиетил)- 4-метилтиазол

Country Status (26)

Country Link
US (1) US5385921A (bg)
EP (1) EP0619734B1 (bg)
JP (1) JP3094077B2 (bg)
AT (1) ATE164066T1 (bg)
AU (1) AU657490B2 (bg)
BG (1) BG97446A (bg)
CA (1) CA2088775A1 (bg)
CZ (1) CZ279586B6 (bg)
DE (1) DE69129126T2 (bg)
DK (1) DK0619734T3 (bg)
ES (1) ES2114891T3 (bg)
FI (1) FI930608A0 (bg)
HU (1) HUT65821A (bg)
IE (1) IE912818A1 (bg)
IL (1) IL99169A (bg)
IS (1) IS3743A7 (bg)
LT (1) LT3978B (bg)
LV (1) LV10921B (bg)
NO (1) NO303447B1 (bg)
NZ (1) NZ239329A (bg)
PT (1) PT98688B (bg)
RO (1) RO112994B1 (bg)
RU (1) RU2093155C1 (bg)
SE (1) SE9002659D0 (bg)
SK (1) SK8793A3 (bg)
WO (1) WO1992003134A1 (bg)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901658D0 (sv) * 1999-05-06 1999-05-06 Astra Ab New formulation
SE9904177D0 (sv) * 1999-11-18 1999-11-18 Astra Ab Novel compounds
WO2002083863A2 (en) 2001-04-17 2002-10-24 Sepracor, Inc. Thiazole and other heterocyclic ligands and use thereof
CN103772313B (zh) * 2014-01-02 2015-10-14 郑桂富 一种4-甲基-5-(2-羟乙基)噻唑的合成方法
CN112262814A (zh) * 2020-10-26 2021-01-26 宜宾学院 油樟叶渣发酵床养鸡方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2825966A1 (de) * 1978-06-14 1980-01-03 Basf Ag Saures galvanisches nickelbad, das sulfobetaine als glanz- und einebnungsmittel enthaelt
GB8600783D0 (en) * 1986-01-14 1986-02-19 Merck Sharp & Dohme N-methyl-d-aspartate receptor antagonists

Also Published As

Publication number Publication date
HUT65821A (en) 1994-07-28
EP0619734B1 (en) 1998-03-18
US5385921A (en) 1995-01-31
CZ16693A3 (en) 1994-02-16
FI930608A (fi) 1993-02-11
WO1992003134A1 (en) 1992-03-05
IL99169A (en) 1995-10-31
NO930452L (no) 1993-02-09
IE912818A1 (en) 1992-02-26
IS3743A7 (is) 1992-02-16
CZ279586B6 (cs) 1995-05-17
SE9002659D0 (sv) 1990-08-15
SK8793A3 (en) 1993-07-07
LT3978B (en) 1996-06-25
PT98688A (pt) 1992-07-31
AU8409291A (en) 1992-03-17
LTIP1714A (en) 1995-09-25
NO303447B1 (no) 1998-07-13
JP3094077B2 (ja) 2000-10-03
DE69129126D1 (de) 1998-04-23
NO930452D0 (no) 1993-02-09
FI930608A0 (fi) 1993-02-11
AU657490B2 (en) 1995-03-16
NZ239329A (en) 1994-11-25
ES2114891T3 (es) 1998-06-16
LV10921B (en) 1996-08-20
DE69129126T2 (de) 1998-07-23
RO112994B1 (ro) 1998-03-30
JPH06500097A (ja) 1994-01-06
PT98688B (pt) 1999-01-29
EP0619734A1 (en) 1994-10-19
CA2088775A1 (en) 1992-02-16
ATE164066T1 (de) 1998-04-15
HU9300388D0 (en) 1993-04-28
RU2093155C1 (ru) 1997-10-20
DK0619734T3 (da) 1998-10-05
IL99169A0 (en) 1992-07-15
LV10921A (lv) 1995-12-20

Similar Documents

Publication Publication Date Title
FI932932A (fi) Foerfarande och komposition foer desinfektering av kontaktlinser
AU9130691A (en) Stable suspension formulations for controlled delivery of pharmaceutical compounds
NZ240378A (en) Substituted thiazolidinedione derivatives; pharmaceutical compositions,
BG97446A (bg) Фармацевтични състави на 5-(2-хлор-1-хидроксиетил)- 4-метилтиазол
AU8225391A (en) The use of inositolmonophosphate for the preparing of a medicament effective as a neuropeptide gamma-antagonist
IL98198A0 (en) Pharmaceutical compositions containing a derivative of substituted-l-valyl-l-prolinamide
TR27833A (tr) Antelmintik'lerin uygulanmasina mahsus ''pour-on'' formülasyonu.
EP0650723A3 (en) New pharmaceutical uses of forskolin derivatives.
IL97509A0 (en) Lipid lowering compositions comprising bambuterol
NZ239187A (en) Substituted 2-(9-fluorenonyl)-carbapenem derivatives, pharmaceutical compositions, and intermediates
RU93004984A (ru) Фармацевтическая композиция на основе 5(2-хлор-1-гидроксиэтил)-4-метилтиазола, применение 5-(2-хлор-1-гидроксиэтил)-4-метил-тиазола для лечения, способ лечения, соли 5-(2-хлор-1-гидроксиэтил)-4-метилтиазола
DE3169918D1 (en) Cis-c3",c4"-carbonate derivatives of oleandomycin-y, pharmaceutical compositions containing them, and intermediates therefor
FI930967A0 (fi) Substituerade 6,7-dihydroimidazo(1,5,4-ef)(1,5)bensodiazepin-6-oner, deras framstaellning och farmaceutiska kompositioner
EP0509098A4 (en) Ataractic
IT9022493A0 (it) Composizione farmaceutica a rilascio controllato contenente un sale farmaceuticamente accettabile di buflomedil
MX9203359A (es) Nuevas composiciones farmaceuticas de insulina.
AU636721C (en) Pharmaceutical iodine compositions
IE901230L (en) Ocular hypotensive pharmaceutical compositions
AU4930797A (en) New ellipticine compounds, a process for their preparation and pharmaceutical compositions containing them
IT9048110A0 (it) Composizioni farmaceutiche per la somministrazione rettale di calcitonina
IT1100372B (it) Associazione di antibiotici caratterizzata da diminuita tossicita',e composizioni farmaceutiche relative